557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
Patrizia Froesch(Institute of Oncology Research), Martin Früh, Q. Li(Swiss Group For Clinical Cancer Research), Ilaria Colombo(Ente Ospedaliero Cantonale), Michael Mark(Kantonsspital Graubünden), Oliver Gautschi(University of Bern), Helen Thut(University Hospital of Basel), Yannis Metaxas(Kantonsspital Graubünden), Gilles Godar(Swiss Group For Clinical Cancer Research), Sabine Schmid(University of Bern), Sacha I. Rothschild(University Hospital of Basel), C. Sessa(Hospital Clínico Universitario de Valencia), Corinne Rusterholz(Swiss Group For Clinical Cancer Research)
Cited by 1
Related Papers
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|288